MGTX Logo

MeiraGTx Holdings plc (MGTX) 

NASDAQ
Market Cap
$450.16M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
53 of 775
Rank in Industry
39 of 432

Largest Insider Buys in Sector

MGTX Stock Price History Chart

MGTX Stock Performance

About MeiraGTx Holdings plc

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; degenerative diseases; neurodegenerative diseases, such as amyotrophic lateral sclerosis; and Parkinson's diseases. Its programs in clinical development include Phase 1/2 clinical stage programs in Achromatopsia, X-Linked Retinitis Pigmentosa, …

Insider Activity of MeiraGTx Holdings plc

Over the last 12 months, insiders at MeiraGTx Holdings plc have bought $5M and sold $0 worth of MeiraGTx Holdings plc stock.

On average, over the past 5 years, insiders at MeiraGTx Holdings plc have bought $10.71M and sold $7.04M worth of stock each year.

Highest buying activity among insiders over the last 12 months: PERCEPTIVE ADVISORS LLC () — $75M.

The last purchase of 1,250,000 shares for transaction amount of $5M was made by PERCEPTIVE ADVISORS LLC () on 2024‑08‑12.

List of Insider Buy and Sell Transactions, MeiraGTx Holdings plc

2024-08-12Purchase
1.25M
1.9341%
$4.00$5M+5.75%
2023-05-05Purchase
4.35M
8.3577%
$5.75$25M-1.95%
2022-06-03PurchaseCHIEF MEDICAL OFFICER
6
<0.0001%
$7.89$47-6.73%
2022-05-25PurchaseGENERAL COUNSEL AND SECRETARY
1,000
0.0022%
$7.94$7,940-5.28%
2021-11-17SalePresident and CEO
30,000
0.0679%
$19.86$595,800-51.18%
2021-11-16SalePresident and CEO
30,000
0.0678%
$19.97$599,144-51.10%
2021-10-20SaleCFO & COO
41,400
0.0941%
$21.05$871,371-40.21%
2021-10-19SaleCFO & COO
2,600
0.0062%
$20.07$52,182-33.88%
2021-10-18SalePresident and CEO
60,000
0.1271%
$17.36$1.04M-31.36%
2021-10-18SaleChief Development Officer
24,000
0.0526%
$17.95$430,800-31.36%
2021-07-20SaleChief Development Officer
18,780
0.0419%
$15.06$282,827-10.03%
2021-07-13SaleChief Development Officer
5,220
0.0119%
$15.04$78,509-6.75%
2021-06-09SalePresident and CEO
8,306
0.0187%
$15.04$124,922-6.21%
2021-06-08SalePresident and CEO
40,360
0.0917%
$15.02$606,207-5.14%
2021-06-08SaleChief Development Officer
10,080
0.0229%
$15.01$151,301-5.14%
2021-06-07SalePresident and CEO
11,334
0.026%
$15.03$170,350-4.05%
2021-06-07SaleChief Development Officer
2,084
0.0048%
$15.02$31,302-4.05%
2021-04-30SaleChief Development Officer
741
0.0017%
$15.01$11,122-4.34%
2021-04-29SaleChief Development Officer
1,405
0.0032%
$15.02$21,103-4.47%
2021-04-28SaleChief Development Officer
3,772
0.0087%
$15.14$57,108-3.43%

Insider Historical Profitability

<0.0001%
PERCEPTIVE ADVISORS LLC
12531103
16.034%
$5.7660<0.0001%
PERCEPTIVE LIFE SCIENCES MASTER FUND LTD10 percent owner
6007746
7.6871%
$5.7610+18.44%
Seligman Nicoledirector
5000
0.0064%
$5.7610<0.0001%
Zeldin Robert KCHIEF MEDICAL OFFICER
5000
0.0064%
$5.7610<0.0001%
Wollin Robert JGENERAL COUNSEL AND SECRETARY
1000
0.0013%
$5.7610<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Perceptive Advisors$68.72M17.6211.33M0%+$00.04
Johnson & Johnson$40.31M10.336.64M0%+$00.94
Adage Capital Partners Gp L L C$32.12M8.235.29M0%+$00.06
Prosight Management Lp$24.39M6.254.02M-0.82%-$202,816.916.8
683 Capital Management Llc$15.18M3.892.5M0%+$01.64
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.